These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11060669)

  • 41. Interferon beta-1a in primary progressive multiple sclerosis.
    Leary SM; Thompson AJ
    J Neurol Sci; 2003 Feb; 206(2):215-6. PubMed ID: 12559514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis.
    Murdoch D; Lyseng-Williamson KA
    Drugs; 2005; 65(9):1295-312. PubMed ID: 15916455
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
    Goodin DS; Frohman EM; Garmany GP; Halper J; Likosky WH; Lublin FD; Silberberg DH; Stuart WH; van den Noort S;
    Neurology; 2002 Jan; 58(2):169-78. PubMed ID: 11805241
    [No Abstract]   [Full Text] [Related]  

  • 44. [The role of interferon beta in the treatment of multiple sclerosis].
    Seeldrayers P
    Rev Med Brux; 1999 Sep; 20(4):A264-7. PubMed ID: 10523902
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response.
    Goodin DS
    Drugs; 2001; 61(12):1693-703. PubMed ID: 11693459
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Guideline for the use of beta-interferons in patients with multiple sclerosis--a South African proposal.
    Multiple Sclerosis Advisory Committee of the Neurological Association of South Africa (NASA)
    S Afr Med J; 2004 Nov; 94(11):917-21. PubMed ID: 15587456
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
    Durelli L; Verdun E; Barbero P; Bergui M; Versino E; Ghezzi A; Montanari E; Zaffaroni M;
    Lancet; 2002 Apr; 359(9316):1453-60. PubMed ID: 11988242
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
    Tilbery CP; Moreira MA; Mendes MF; Lana-Peixoto MA
    Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness.
    Clegg A; Bryant J
    Expert Opin Pharmacother; 2001 Apr; 2(4):623-39. PubMed ID: 11336612
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies.
    Wiendl H; Kieseier BC
    Expert Opin Investig Drugs; 2003 Apr; 12(4):689-712. PubMed ID: 12665424
    [TBL] [Abstract][Full Text] [Related]  

  • 53. History of modern multiple sclerosis therapy.
    Lublin F
    J Neurol; 2005 Sep; 252 Suppl 3():iii3-iii9. PubMed ID: 16170498
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disease modifying therapies in multiple sclerosis.
    Fox RJ; Fisher E; Rudick R
    Neurology; 2002 Aug; 59(3):471-2; author reply 472-3. PubMed ID: 12177396
    [No Abstract]   [Full Text] [Related]  

  • 55. Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG].
    Rieckmann P; Toyka KV
    Eur Neurol; 1999; 42(3):121-7. PubMed ID: 10529535
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Treatment of multiple sclerosis. The present and the future. Study Group on Diagnosis and Therapy of Multiple Sclerosis].
    Cazzato G; Antonello RM; Zorzon M; Torre P; Zivadinov R; Moretti R; Bragadin LM; De Masi R; Nasuelli D
    Recenti Prog Med; 1999 Oct; 90(10):538-44. PubMed ID: 10592740
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
    Frese A; Bethke F; Lüdemann P; Stögbauer F
    Neurology; 1999 Nov; 53(8):1892-3. PubMed ID: 10563657
    [No Abstract]   [Full Text] [Related]  

  • 59. Therapeutic approaches to secondary progressive multiple sclerosis.
    Lublin FD
    Mult Scler; 2002 Feb; 8(1):88-90. PubMed ID: 11936495
    [No Abstract]   [Full Text] [Related]  

  • 60. [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo].
    Tedeholm H; Skoog B; Hillert J; Runmarker B; Stawiarz L; Oluf A
    Lakartidningen; 2007 May 30-Jun 3; 104(22):1684-8. PubMed ID: 17601317
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.